Critical Path Institute® (C-Path) today announced key leadership appointments: Diane Stephenson, Ph.D., has been promoted to Vice President of Neurology, and Nadine Tatton, Ph.D., has been welcomed as the new Executive Director of C-Path’s Critical Consortium Path for Alzheimer’s disease (CPAD).
With more than 30 years of specialized research in neuroscience and drug development and nearly 15 years as Executive Director of the Critical Path for Parkinson’s Consortium (CPP), Dr. Stephenson has been an extraordinary partner in advancing our understanding of neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD). Her leadership in guiding the advancement of CPP through collaboration among all stakeholders has broadened treatment pathways and deepened scientific knowledge in these areas.
As Vice President of Neurology, Dr. Stephenson will continue to guide C-Path’s brain health initiatives, applying her expertise in neuroimaging, neuropathology, digital health technologies and translational model characterization to advance C-Path’s research goals. Importantly, she will continue to serve as Executive Director of CPP, ensuring continued strategic alignment with C-Path’s mission.
It is a great privilege to advance my career at C-Path, an organization at the forefront of developing treatments for neurodegenerative diseases. I look forward to this new chapter, where I will continue to build on our collective expertise across academia, industry and regulatory agencies to deepen our impact on patient care.”
Diane Stephenson, Ph.D., vice president of neurology
Dr. Nadine Tatton brings more than two decades of expertise in drug development, strategic leadership and neurodegenerative disease research to her new role as Executive Director of CPAD. Dr. Tatton received her Ph.D. in physiology (neuroscience) from the University of Toronto and completed post-doctoral studies in spinal cord research and molecular neuroscience. Throughout her career, she has held leadership positions in both academic and industrial settings, advancing clinical programs for diseases including Alzheimer’s, frontotemporal dementia (FTD) and Parkinson’s.
Before joining C-Path, Tatton was medical director of immunoneurology at Alector, Inc., where she worked on novel therapeutic approaches targeting neurodegenerative diseases. Her extensive experience also includes her role as Scientific Director at the Association for Frontotemporal Degeneration, where she led collaborations to advance research into FTD disorders and helped build the FTD Disorders Registry. Dr. Tatton’s diverse background uniquely positions her to lead CPAD in its mission to advance innovative regulatory science that accelerates drug development for Alzheimer’s disease.
“I am honored to join C-Path and lead the CPAD Consortium in its mission to drive therapeutic innovation for Alzheimer’s disease,” said Dr. Tatton. “There is so much momentum in AD research today and I look forward to working with our global collaborators in industry, regulators and academia to push the boundaries of what is possible in drug development for the Alzheimer’s disease.”
C-Path CEO Klaus Romero, MD, MS, FCP, also shared his excitement about the appointments, saying, “Dr. Stephenson’s promotion to Vice President of Neurology aligns with C-Path’s strategy to further our collaborative approach to support continued innovation in tools that can further accelerate drug development for neurodegeneration. As Executive Director of CPAD, Dr. Tatton will enable C-Path to launch new initiatives and further our core capabilities in data-driven collaboration to accelerate drug development in Alzheimer’s disease, we continue to develop tools and strategies that address the unmet challenges in neurodegenerative research.”
Both appointments take effect immediately, with Drs. Stephenson and Tatton continue their important work in neurology, Parkinson’s and Alzheimer’s disease research, with an emphasis on patient-centered strategies.